October 2009 clinical trials update

By Jim Hughes
LRG Clinical Trials Coordinator

Two important new trials are highlighted in separate articles in this month’s newsletter:

• The REGISTER trial in Australia, New Zealand and South Korea for newly diagnosed advanced GIST.
• The new five year adjuvant imatinib study recently opened in the United States for newly resected patients. (NCT00867113)

Other GIST clinical trial news includes:
• The Phase 3 imatinib with or without Bevacizumab trial has closed to accrual in the US and Canada. No reason was given. Accrual had not been as high as expected. (NCT00324987)
• A Nilotinib Pharmacokinetic (PK) study has been started in Japan. Researchers will look at the effect of surgery on Nilotinib PK. They are investigating how prior surgery might affect nilotinib absorption. (NCT00976612)
• Radboud University Hospital in the Netherlands has an ongoing palliative study (newly listed) that is investigating the link between angiogenesis inhibitors sunitinib and sorafenib and fatigue and depression in several cancers including GIST. (NCT00979329)
• Pfizer has added detailed study results to two major sunitinib trials including the phase 3 registration trial.
• The Pfizer treatment-use protocol for Sutent access for GIST patients remains open in India in Mumbai and New Delhi. (NCT00094029)

View the Clinical Trials Database for a full, searchable list of GIST Clinical Trials.